Lung Cancer

Research suggests stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models and lead to better treatment for non-small cell lung cancer.

The awards recognize faculty members’ outstanding clinical research and promising future in oncology.

The modeling study looks at the benefits and harms associated with various low-dose computed tomography screening strategies—identifying those that result in the most benefits for a given level of screening.

A new inhibitor designed to target what’s been called an “undruggable” genetic mutation showed promising activity against advanced cancers with this mutation.

Changing the way individuals are selected to be screened for lung cancer could prevent 14% of lung cancer deaths per year.

In the first large, randomized trial to look at immunotherapy as a first-line cancer treatment, researchers found that adding the immunotherapy drug pembrolizumab to chemotherapy for advanced lung cancer led to better tumor control and overall survival than chemotherapy followed by pembrolizumab.